Jul 10, 2026 11:23AM
Jul 10, 2026 11:23AM
May 18, 2026 08:00AM
May 14, 2026 10:55AM
Apr 20, 2026 06:45AM
Apr 20, 2026 06:45AM
Feb 27, 2026 10:04AM PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
Feb 27, 2026 10:00AM
Dec 17, 2025 06:45AM
Nov 21, 2025 01:24PM
Nov 21, 2025 01:24PM
Oct 21, 2025 07:30PM
Oct 21, 2025 07:30PM
Oct 18, 2025 10:30AM PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
Oct 1, 2025 02:00AM
Aug 12, 2025 05:30AM
Feb 10, 2025 05:01PM
Feb 10, 2025 05:00PM
Jan 30, 2024 09:00PM
Jan 26, 2024 12:01PM
Jan 26, 2024 12:00PM European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Jan 26, 2024 12:00PM
Dec 21, 2023 06:30PM
Dec 15, 2023 05:00PM
Nov 15, 2023 06:37PM
Aug 7, 2023 09:00AM
Jul 11, 2023 07:00PM
Apr 30, 2023 09:24PM Astellas Pharma to acquire Iveric Bio (ISEE) for $5.9 billion
Apr 30, 2023 07:00PM
Apr 30, 2023 07:00PM
Jan 23, 2023 06:30PM
Oct 24, 2022 07:30PM
Oct 24, 2022 07:30PM
Jun 8, 2022 08:00AM
Feb 7, 2022 06:00PM Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease
Dec 1, 2021 07:00PM
Jul 30, 2021 08:00AM
Oct 20, 2020 08:00AM
Oct 14, 2020 11:00PM
Jan 15, 2020 08:22AM
Jan 14, 2020 02:07AM
Dec 26, 2019 07:30PM Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
Dec 2, 2019 06:01PM
Oct 28, 2019 09:00AM
Feb 28, 2019 05:34PM
Dec 14, 2018 01:00PM
Aug 10, 2018 07:00AM
Apr 25, 2018 11:00PM
Feb 13, 2018 08:00PM Astellas Acquires Universal Cells, Inc.
Jan 30, 2018 10:00PM

1,174,205 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All